Pure Global
NCT04778787

Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention

Impact of Sodium-glucose Cotransporter Type 2 Inhibitors on the Course of Cardiorenal Syndrome in Acute Decompensation of Chronic Heart Failure
I.M. Sechenov First Moscow State Medical University·Phase 4·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Congestive Heart Failure
Drug/Device/Intervention
Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
I.M. Sechenov First Moscow State Medical University
Location
Moscow,Moscow, Russian Federation
Timeline & enrollment
Phase
Phase 4
Start date
Jan 01, 2021
End date
Jan 01, 2022
Enrollment
100 participants
Primary outcome

admission to the intensive care unit due to worsening heart failure during the current hospitalization,death due to heart failure

Summary

The effect of sodium-glucose cotransporter type 2 inhibitors (SGLT2i) on the parameters of
 renal function in acute decompensation of chronic heart failure (CHF) compared to standard
 therapy will be analyzed. Based on the dynamics of the clinical condition, the duration of
 hospitalization, and blood biochemical parameters (creatinine, urea, uric acid, potassium,
 sodium, N-terminal pro-brain natriuretic peptide NT-proBNP) conclusions will be drawn about
 the possibility of using SGLT2i in this group of patients.

ICD-10 classifications
Congestive heart failureHeart failureHypertensive heart disease with (congestive) heart failureHypertensive heart and renal disease with (congestive) heart failureHeart failure, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04778787
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04778787 through Pure Global AI's free database. This Phase 4 trial is sponsored by I.M. Sechenov First Moscow State Medical University and is currently Recruiting. The study focuses on Congestive Heart Failure. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.